54 results about "Cerebral vasospasm" patented technology

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF). The methods provide for efficiently removing target compounds from CSF. The systems provide for a multilumen flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents. The invention finds use as a diagnostic, therapeutic and drug delivery platform for a variety of diseases affecting the CNS by accessing the CSF space. Exemplified disease conditions treatable by the present CSF processing systems and methods include, but are not limited to: Cerebral Vasospasm, Guillain Bane Syndrome, illustrating multi-lumen lumbar approach Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Spinal Cord Injury, Traumatic Brain Injury, Stroke, Cancer affecting the brain or spinal cord, Prion disease, Encephalitis from various causes, Meningitis from various causes, diseases secondary to enzymatic or metabolic imbalances, Biological Warfare, etc. For the first time, the present invention offers patients a disease-modifying, disruptive technology treatment platform that addresses the known disease pathogenesis of a number of neurologic conditions to which there are presently limited and ineffective treatment options.

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, inflammation, and vasoconstriction. Particularly, this invention is directed to methods of treating cardiovascular diseases or conditions such as stent restenosis and thrombosis, vascular thrombosis, cerebral vasospasm, atherosclerosis, systemic hypertension, cardiac hypertrophy, and sexual dysfunction. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease.

This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia/reperfusion (I/R) injury of various tissues (e.g., I/R injury of heart muscle associated with heart attack or cardiac surgery, I/R injury of brain tissue associated with stroke, I/R injury of liver tissue, skeletal muscles, etc.), septic shock, anaphylactic shock, neurodegenerative diseases (e.g., Alzheimer's and Parkinson's diseases), neuronal injury, atherosclerosis, diabetes, multiple sclerosis, autoimmune uveitis, pulmonary fibrosis, oobliterative bronchiolitis, bronchopulmonary dysplasia (BPD), amyotrophic lateral sclerosis (ALS), sepsis, inflammatory bowel disease, arthritis, allograft rejection, autoimmune myocarditis, myocardial inflammation, pulmonary granulomatous inflammation, influenza- or HSV-induced pneumonia, chronic cerebral vasospasm, allergic encephalomyelitis, central nervous system (CNS) inflammation, Heliobacterium pylori gastritis, necrotizing entrerocolitis, celliac disease, peritonitis, early prosthesis failure, inclusion body myositis, preeclamptic pregnancies, skin lesions with anaphylactoid purpura, nephrosclerosis, ileitis, leishmaniasis, cancer, and related disorders.

A method of treating cerebral vasospasm includes delivering at least a first blood vessel including an expandable segment to a position within a blocked or constricted portion of a vessel and transitioning the expandable segment from a collapsed configuration to an expanded configuration to dilate the vessel and to restore adequate blood flow through the vessel. The expandable segment has a pre-set outer diameter substantially equal to or less than an inner diameter of the vessel. Additionally, the expandable segment is configured to expand with a minimal amount of radial force necessary to contact and expand the inner walls of the vessel. After dilation of the vessel, the device is removed from the patient's body. If necessary, additional blood vessel dilation devices each including an expandable segment having a pre-set outer diameter greater than the previous device's expandable segment can be used in order of increasing pre-set outer diameter of the expanded segment to further dilate the blocked or constricted portion of the vessel and restore blood flow through the vessel. Once adequate blood flow through the vessel has been restored, the blood vessel dilation device is withdrawn.

A brain-protective agent containing an NF-kappaB decoy. In brain diseases, the brain can be particularly effectively protected against brain disorders (for example, cerebral vasospasm following a subrachnoidal hemorrhage and apoptosis of the nerve cells following a cerebrovasucular accident or serious head injury) caused by the undesired activation of cytokines or cell adhesion factors which are regulated by NF-kappaB by administering the brain-protective agent containing an NF-kappaB decoy, i.e., a compound antadonistic specifically to a nucleic acid to which NF-kappaB binds.

The invention relates to a heath-care pillow, particularly relates to a gastrodia tuber refreshment pillow, belongs to daily necessities technology field. The refreshment pillow is prepared by washing, drying and packaging of gastrodia tuber, earthworm, grassleaf sweelflag rhizome, polygala root, prepared rehmannia root, desertliving cistanche. The gastrodia tuber is the main chinese medicine for relieving cerebral vasospasm and tonicity, has function in calmness, hypnosis, anticonvulsion, decompression, analgecize, and function of resisting ischemia and hypoxia, reducing vascular resistance, increasing cerebral blood flow, improving microcirculation; the earthworm has function in calmness, anticonvulsion, prevention of insomnia, analgecize; the polygala root has function of anti-aging, anti-dementia and protecting brain activity; the grassleaf sweelflag rhizome has function of calmness, refreshing the brain, improving intelligence, inhibition of platelet aggregation; the rehmannia root has regulation funtion to hormone metabolism and function of protecting heart and brain tissues; the desertliving cistanche has function of anti-aging and anti-oxidation. The six chinese medicines have anti-hypoxia function by expanding cerebral vascular, which is helpful for preventing dizziness and headache caused by brain tissue hypoxia.

The invention is directed to the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compounds which are both a CB1 agonist and a CB2 agonist; and mixtures thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.

Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including subarachnoid hemorrhage, intracerebral hemorrhage, and intraventricular hemorrhage and other brain disorders. The invention encompasses methods for treating cerebral vasospasm by administration of at least one ApoE or ApoE mimetic peptide.

The present invention relates to a compound having a highly selective Rho-kinase inhibiting activity and being useful as a therapeutic agent for a disease such as hypertension, pulmonary hypertension, cerebral vasospasm, cardiac angina, cardiac failure, arteriosclerosis, glaucoma, dysuria, asthma, or erectile dysfunction, and a drug containing the compound.

Provided is a homopiperazine derivative represented by General Formula (1), an acid addition salt thereof, or a solvate of the derivative or the salt:

(wherein R¹ represents an amino acid residue; R² represents a hydrogen atom or an alkyl group; R³ represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a halogen atom, a nitrile group, or a hydroxyl group; and R⁴ represents a hydrogen atom, a halogen atom, or a hydroxyl group).

The present invention relates to a stable naloxone powder injection. The naloxone powder injection described by said invention is formed from naloxone or its physiologically-aceptable salt and pharmacologically-allowable injection auxiliary material. It can be extensively used for curing various diseases of acute alcoholism, cerebrovascular accident, ischemic encephalopathy, coma, craniocerebral injury and imminent serious diseases, and can be used for removing respiratory inhibition and inducing awavening after combined anesthesia and operation.

The present invention discloses a preparation method of Chinese medicine preparation for treating ischemic cardiovascular and cerebrovascular diseases. The method comprises the following steps of: extracting and refining the ginkgo leaf and szechuan lovage rhizome to obtain the extract with higher content of active ingredient, adding the extract with pharmaceutic adjuvant with a ratio of 1 : 1 - 5 and 1 : 1 - 8, mixing uniformly, and preparing into soft capsule and pills respectively. The Chinese medicine preparation has significant effect on the treatment of ischemic cardiovascular and cerebrovascular diseases, coronary heart disease, angina pectoris, cerebral embolism, cerebral vasospasm and the like, no toxic and side-effect, the production technology is simple, and the quality control of product is convenient.

The present invention discloses a Chinese medicine injection for curing acute cerebral hemorrhage. It is made of (by weight ratio) antelope horn 1-70, moutan root bark 4-164, acorus root 2-60 and gardenia fruit 10-120 as raw material. Said invention also discloses its preparation method, and said injection possesses the good therapeutic effect.

A nimodipine injection in the form of emulsion for treating hemorrhagic cerebrovascular diseases, hypertension, senile dementia, etc is prepared from nimodipine, plant oil for injection, emulsifier and isotonic regulator through dissolving nimodipine in said plant oil and proportionally mixing others.

The invention is directed to nonpeptide substituted benzazepines of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension, among others disclosed. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

The invention is directed to pharmaceutical compositions comprising pharmacologically effective quantities of each of a) at least one KATP channel modulator as a first active agent and b) at least one CBx modulator as a second active agent. The invention further relates to the use of such compositions and to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans by administering such compositions to subjects in need thereof. The invention also is directed to processes of manufacturing such compositions.